Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
Mobile, AL
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
Gilbert, AZ
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
Little Rock, AR
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
San Diego, CA
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
Orange, CA
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
Tampa, FL
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
Macon, GA
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
Macon, GA
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
Destrehan, LA
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
Destrehan, LA
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
Brighton, MA
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
Brighton, MA
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
Brockton, MA
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
Brockton, MA
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
Kalamazoo, MI
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
St. Louis, MO
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
West Seneca, NY
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
West Seneca, NY
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
West Chester, PA
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
West Chester, PA
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
Austin, TX
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated:  1/29/2013
Clinical Research Facility
mi
from
San Antonio, TX
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Status: Enrolling
Updated: 1/29/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Guided Self-Help for Functional Neurological Symptoms
Guided Self-Help for Functional Neurological Symptoms: A Randomized Controlled Efficacy Trial
Status: Enrolling
Updated:  1/31/2013
Mayo Clinic
mi
from
Phoenix, AZ
Guided Self-Help for Functional Neurological Symptoms
Guided Self-Help for Functional Neurological Symptoms: A Randomized Controlled Efficacy Trial
Status: Enrolling
Updated: 1/31/2013
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 111
mi
from
Gilbert, AZ
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 111
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 139
mi
from
Downey, CA
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 139
mi
from
Downey, CA
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 112
mi
from
Irvine, CA
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 112
mi
from
Irvine, CA
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 119
mi
from
Long Beach, CA
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 119
mi
from
Long Beach, CA
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 134
mi
from
Fairfield, CT
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 134
mi
from
Fairfield, CT
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 124
mi
from
New London, CT
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 124
mi
from
New London, CT
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 114
mi
from
Maitland, FL
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 114
mi
from
Maitland, FL
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 120
mi
from
Port Charlotte, FL
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 120
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 130
mi
from
Sunrise, FL
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 130
mi
from
Sunrise, FL
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 115
mi
from
Tampa, FL
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 115
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 107
mi
from
Elk Grove Village, IL
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 107
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 132
mi
from
Northbrook, IL
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 132
mi
from
Northbrook, IL
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 118
mi
from
Kansas City, KA
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 118
mi
from
Kansas City, KA
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 140
mi
from
Louisville, KY
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 140
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 103
mi
from
Golden Valley, MN
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 103
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 125
mi
from
Charlotte, NC
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 125
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 141
mi
from
Raleigh, NC
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 141
mi
from
Raleigh, NC
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 106
mi
from
Cleveland, OH
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 106
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 135
mi
from
Dayton, OH
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 135
mi
from
Dayton, OH
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 132
mi
from
Abington, PA
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 132
mi
from
Abington, PA
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 109
mi
from
Indiana, PA
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 109
mi
from
Indiana, PA
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 137
mi
from
Franklin, TN
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 137
mi
from
Franklin, TN
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 122
mi
from
Charlottesville, VA
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 122
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis
Validation of a Hand-Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics
Status: Enrolling
Updated:  2/4/2013
MS Center at Evergreen Hospital
mi
from
Kirkland, WA
Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis
Validation of a Hand-Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics
Status: Enrolling
Updated: 2/4/2013
MS Center at Evergreen Hospital
mi
from
Kirkland, WA
Click here to add this to my saved trials
The Use of Neuromuscular Electrical Stimulation to Reverse Muscle Atrophy in Patients With Rheumatoid Arthritis
The Use of Neuromuscular Electrical Stimulation to Reverse Muscle Atrophy in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  2/5/2013
Physical Therapy Department
mi
from
Pittsburgh, PA
The Use of Neuromuscular Electrical Stimulation to Reverse Muscle Atrophy in Patients With Rheumatoid Arthritis
The Use of Neuromuscular Electrical Stimulation to Reverse Muscle Atrophy in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 2/5/2013
Physical Therapy Department
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hyperthermia and the Amelioration of Autism Symptoms
Hyperthermia and the Amelioration of Autism Symptoms
Status: Enrolling
Updated:  2/5/2013
Montefiore Medical Center, Albert Einstein College of Medicine
mi
from
Bronx, NY
Hyperthermia and the Amelioration of Autism Symptoms
Hyperthermia and the Amelioration of Autism Symptoms
Status: Enrolling
Updated: 2/5/2013
Montefiore Medical Center, Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA)
Prospective, International, Multi-centre Study on ASAS Classification Criteria for SpA
Status: Enrolling
Updated:  2/12/2013
Case Western Reserve University at MetroHealth Medical Centre
mi
from
Cleveland, OH
Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA)
Prospective, International, Multi-centre Study on ASAS Classification Criteria for SpA
Status: Enrolling
Updated: 2/12/2013
Case Western Reserve University at MetroHealth Medical Centre
mi
from
Cleveland, OH
Click here to add this to my saved trials
Neural Correlates of Cognitive Rehabilitation in PTSD
Neural Correlates of Cognitive Rehabilitation in Posttraumatic Stress Disorder
Status: Enrolling
Updated:  2/12/2013
VA Connecticut Healthcare System, 151E
mi
from
West Haven, CT
Neural Correlates of Cognitive Rehabilitation in PTSD
Neural Correlates of Cognitive Rehabilitation in Posttraumatic Stress Disorder
Status: Enrolling
Updated: 2/12/2013
VA Connecticut Healthcare System, 151E
mi
from
West Haven, CT
Click here to add this to my saved trials
Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients?
The Effect of a Dexmedetomidine-focussed Sleep Protocol* on Delirium Incidence and Healthcare Costs in Critically Ill Patients: A Prospective Randomized, Double-blind, Pilot Study.
Status: Enrolling
Updated:  2/13/2013
Tufts Medical Center
mi
from
Boston, MA
Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients?
The Effect of a Dexmedetomidine-focussed Sleep Protocol* on Delirium Incidence and Healthcare Costs in Critically Ill Patients: A Prospective Randomized, Double-blind, Pilot Study.
Status: Enrolling
Updated: 2/13/2013
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Albumin for Intracerebral Hemorrhage Intervention
Albumin for Intracerebral Hemorrhage Intervention
Status: Enrolling
Updated:  2/14/2013
Georgetown University Hospital
mi
from
Washington,
Albumin for Intracerebral Hemorrhage Intervention
Albumin for Intracerebral Hemorrhage Intervention
Status: Enrolling
Updated: 2/14/2013
Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels
Nephrogenic Systemic Fibrosis and Gadolinium—A Medical Record Review With Analysis of Existing Skin and Other Tissue Specimens to Assess Potential Causative or Associated Factors
Status: Enrolling
Updated:  2/14/2013
Northwestern University, Feinberg School of Medicine, Department of Dermatology
mi
from
Chicago, IL
Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels
Nephrogenic Systemic Fibrosis and Gadolinium—A Medical Record Review With Analysis of Existing Skin and Other Tissue Specimens to Assess Potential Causative or Associated Factors
Status: Enrolling
Updated: 2/14/2013
Northwestern University, Feinberg School of Medicine, Department of Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials
The Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury
Phase IV Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury
Status: Enrolling
Updated:  2/20/2013
Brooke Army Medical Center
mi
from
San Antonio, TX
The Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury
Phase IV Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury
Status: Enrolling
Updated: 2/20/2013
Brooke Army Medical Center
mi
from
San Antonio, TX
Click here to add this to my saved trials